drugset / Trial / NCT06644040
A Study of TeriQ Patch in Healthy Adult Female Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This will be a single center, open-label, active-controlled, 3-way, incomplete block, crossover, randomized, and single escalating dose study.
Timeline
- Start
- 2024-10-25
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Forteo Inj. | Unknown | — | Subcutaneous |
| Subject | TeriQ Patch | Unknown | 28.2 ug | Other |
| Subject | TeriQ Patch | Unknown | 56.5 ug | Other |
| Subject | TeriQ Patch | Unknown | 113 ug | Other |
| Comparator | Teribone Inj. | Unknown | — | Subcutaneous |